-
公开(公告)号：US12077543B2
公开(公告)日：2024-09-03
申请号：US17706690
申请日：2022-03-29
Applicant: Asana BioSciences, LLC
Inventor： Scott K. Thompson , Tony Priestley , Mrinalkanti Kundu , Ashis Saha , Suvadeep Nath
IPC: C07D487/04 , A61K31/519 , A61P11/00 , A61P11/06 , A61P11/08 , A61P25/00 , A61P25/04 , A61P29/00 , A61P35/00 , C07D519/00
CPC classification number: C07D487/04 , C07D519/00
Abstract: The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.
-
公开(公告)号：US20240165055A1
公开(公告)日：2024-05-23
申请号：US18424468
申请日：2024-01-26
Applicant: Verona Pharma PLC
Inventor： Tara Renae RHEAULT , Kathleen RICKARD , Thomas BENGTSSON
IPC: A61K31/137 , A61K9/00 , A61K31/519 , A61K31/573 , A61K47/26 , A61P11/08
CPC classification number: A61K31/137 , A61K9/0078 , A61K31/519 , A61K31/573 , A61K47/26 , A61P11/08
Abstract: The present invention relates to a compound for use in a method of increasing trough lung function in a patient suffering from chronic obstructive pulmonary disease (COPD), wherein the compound is ensifentrine or a pharmaceutically acceptable salt thereof. The invention also relates to a compound for use in treating chronic obstructive pulmonary disease (COPD) in a patient, wherein: the compound is ensifentrine or a pharmaceutically acceptable salt thereof and the patient is susceptible to disturbed sleep.
-
公开(公告)号：US20240092791A1
公开(公告)日：2024-03-21
申请号：US18267185
申请日：2021-12-13
Applicant: CHIESI FARMACEUTICI S.P.A.
Inventor： Fabio RANCATI , Alessandro ACCETTA , Anna Maria CAPELLI , Daniele PALA , Christine EDWARDS , Adele Elisa PASQUA , Prashant Bhimrao KAPADNIS , Arnaud Jean Francois Auguste CHEGUILLAUME , David Edward CLARK
IPC: C07D491/048 , A61P11/08
CPC classification number: C07D491/048 , A61P11/08
Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
-
4.发明公开公开(公告)号：US20240084306A1
公开(公告)日：2024-03-14
申请号：US18330588
申请日：2023-06-07
Applicant: Onspira Therapeutics, Inc.
Inventor： Roy C. LEVITT, JR.
IPC: C12N15/113 , A61K9/00 , A61K31/70 , A61K31/7088 , A61K31/713 , A61K38/17 , A61K38/20 , A61K39/395 , A61K45/06 , A61P11/08 , C07K14/715
CPC classification number: C12N15/1136 , A61K9/007 , A61K9/0075 , A61K9/0078 , A61K9/008 , A61K31/70 , A61K31/7088 , A61K31/713 , A61K38/1793 , A61K38/20 , A61K38/2006 , A61K39/3955 , A61K45/06 , A61P11/08 , C07K14/7155 , C12N15/113 , C07K2319/30 , C12N2310/11 , C12N2310/14 , C12N2320/30
Abstract: The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer.
-
5.发明公开公开(公告)号：US20230372377A1
公开(公告)日：2023-11-23
申请号：US18138671
申请日：2023-04-24
Applicant: ATOPIC MEDICAL, INC.
Inventor： Thomas J. Borody , Debra A. Peattie
IPC: A61K31/7048 , A61K45/06 , A61K9/127 , A61K9/107 , A61K9/00 , A61P31/16 , A61K9/51 , A61P11/02 , A61P11/06 , A61P11/12 , A61P11/08
CPC classification number: A61K31/7048 , A61K45/06 , A61K9/1274 , A61K9/1075 , A61K9/008 , A61P31/16 , A61K9/51 , A61P11/02 , A61P11/06 , A61P11/12 , A61P11/08 , A61K9/0075 , A61K9/5153 , A61K9/0078 , A61K9/5146
Abstract: Disclosed are compositions and methods for treating, amelioriating, reversing and/or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and/or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.
-
Patent Agency Ranking
公开(公告)号：US11708392B2
公开(公告)日：2023-07-25
申请号：US17012724
申请日：2020-09-04
Applicant: BIONIZ, LLC
Inventor： Yutaka Tagaya , Nazli Azimi
IPC: C07K7/08 , C07K7/06 , C07K14/52 , C07K14/54 , A61K8/64 , A61K38/20 , A61K38/10 , A61K38/00 , A61Q3/00 , A61Q7/00 , A61Q19/00 , A61Q19/08 , A61P1/04 , A61P3/10 , A61P5/14 , A61P11/00 , A61P11/02 , A61P11/06 , A61P11/08 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/10 , A61P17/14 , A61P19/02 , A61P25/00 , A61P25/02 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , A61K47/64
CPC classification number: C07K7/08 , A61K8/64 , A61K38/20 , A61K47/642 , A61K47/643 , A61Q3/00 , A61Q7/00 , A61Q19/00 , A61Q19/004 , A61Q19/08 , C07K7/06 , C07K14/52 , C07K14/54 , A61K38/00 , A61K38/10
Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
-
公开(公告)号：US11524055B2
公开(公告)日：2022-12-13
申请号：US16883695
申请日：2020-05-26
Applicant: Children's Hospital Los Angeles
Inventor： Mark R. Frey , Michael Schumacher
Abstract: Provided herein are methods and compositions for treating disease-states associated with presence of increased number of ErbB4+ pro-inflammatory macrophages in a subject in need thereof. The methods include providing an activator of ErbB4 and administering a therapeutically effective amount of the activator to the subject. The compositions include an activator of ErbB4. In one embodiment, the activation of ErbB4 is Neuregulin-4.
-
公开(公告)号：US20220175735A1
公开(公告)日：2022-06-09
申请号：US17354751
申请日：2021-06-22
Applicant: Proteostasis Therapeutics, Inc.
Inventor： John Miller , Cecilia M. Bastos , Benito Munoz
IPC: A61K31/422 , A61K31/404 , A61K31/4245 , A61K31/47 , A61K31/7036 , A61K45/06 , A61K31/443 , A61P11/06 , A61P11/08 , A61K9/00 , A61K31/341 , A61K31/4192 , A61K31/433 , A61K31/454 , A61K31/5377
Abstract: The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.
-
公开(公告)号：US11344562B2
公开(公告)日：2022-05-31
申请号：US16103630
申请日：2018-08-14
Applicant: Nephron Pharmaceuticals Corporation
Inventor： Ashley Daugherty
Abstract: Compositions and methods for making and using stable, homogeneous budesonide compositions are disclosed.
-
公开(公告)号：US11339169B2
公开(公告)日：2022-05-24
申请号：US16800278
申请日：2020-02-25
Applicant: Asana BioSciences, LLC
Inventor： Scott K. Thompson , Tony Priestley , Mrinalkanti Kundu , Ashis Saha , Suvadeep Nath
IPC: C07D487/04 , C07D519/00 , A61P35/00 , A61P29/00 , A61P25/04 , A61P25/00 , A61P11/08 , A61P11/06 , A61P11/00 , A61K31/519
Abstract: The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.
-
-
-
-
-
-
-
-
-
Search Results
1338
records
(took 0.048 seconds)
